TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23714763

Group type: EXPERIMENTAL
Intervention: Video discharge instructions
Number of subjects: 436

Group type: COMPARATOR
Intervention: Written discharge instructions
Number of subjects: 436
Study: 21558074

Group type: EXPERIMENTAL
Intervention: Bevacizumab-based therapy
Number of subjects: 167
Study: 19247267

Group type: EXPERIMENTAL
Intervention: perindopril/indapamide (2/0.625 mg, daily)
Number of subjects: 62

Group type: COMPARATOR
Intervention: atenolol (50 mg, daily)
Number of subjects: 62
Study: 17512799

Group type: EXPERIMENTAL
Intervention: Eszopiclone 3mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15145099

Group type: EXPERIMENTAL
Intervention: Intravenous beta-blockers before PCI (BB+ group)
Number of subjects: 2082

Group type: COMPARATOR
Intervention: No intravenous beta-blockers before PCI (BB- group)
Number of subjects: 2082
Study: 11187220

Group type: EXPERIMENTAL
Intervention: Mivacurium (bolus dose 0.15 mg/kg followed by continuous infusion)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Atracurium (bolus dose 0.4 mg/kg followed by continuous infusion)
Number of subjects: 45
Study: 9071645

Group type: EXPERIMENTAL
Intervention: Growth hormone (hGH) treatment for 2 years
Number of subjects: 48

Group type: COMPARATOR
Intervention: Comparison sample (not treated with hGH)
Number of subjects: 48
Study: 1532382

Group type: EXPERIMENTAL
Intervention: Hemophan membrane with bicarbonate buffer
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cellulose acetate membrane with bicarbonate buffer
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Hemophan membrane with acetate buffer
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cellulose acetate membrane with acetate buffer
Number of subjects: 22
Study: 3910053

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (G.B.E.) 3 X 40 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nicergoline 5 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31034619

Group type: EXPERIMENTAL
Intervention: Therapist MI-consistent skill in the increasing alcohol-CT class
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Therapist MI-consistent skill in the low sexual risk-CT class
Number of subjects: 164
Study: 29968137

Group type: EXPERIMENTAL
Intervention: Electric cautery (Group C)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Scalpel (Group S)
Number of subjects: 80
Study: 27099272

Group type: EXPERIMENTAL
Intervention: 150 min/wk of aerobic exercise (low dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 300 min/wk of aerobic exercise (high dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 25254899

Group type: EXPERIMENTAL
Intervention: Whole body cryotherapy - 3 min at -110°C
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control - 3 min at 21°C
Number of subjects: 13
Study: 22277570

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg once daily
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study: 21409296

Group type: EXPERIMENTAL
Intervention: m-DOT strategy
Number of subjects: 234

Group type: COMPARATOR
Intervention: Standard self-administration of ART
Number of subjects: 234
Study: 18178950

Group type: EXPERIMENTAL
Intervention: Mupirocin ointment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Polysporin Triple antibiotic ointment
Number of subjects: 200
Study: 16503844

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) with free patches and intensive instructions from nurses
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 174
Study: 12812919

Group type: EXPERIMENTAL
Intervention: Propranolol (titrated to reduce heart rate by 15%)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 37
Study: 11059180

Group type: COMPARATOR
Intervention: Cold pressor test (CPT) - hand immersion in ice water for 1 minute.
Number of subjects: 28

Group type: COMPARATOR
Intervention: High-chilli diet (approximately 15 g/day) for 3 days.
Number of subjects: 28
Study: 8792944

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin 750 mg bid after 72 hours of intravenous antibiotics (group 1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Parenteral therapy alone (group 2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparison group (group 3)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin (group 1)
Number of subjects: 50
Study: 1298468

Group type: EXPERIMENTAL
Intervention: Danggui Funing (DGFN) pill
Number of subjects: 207

Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 540705

Group type: EXPERIMENTAL
Intervention: Iopamidol
Number of subjects: 22

Group type: COMPARATOR
Intervention: Urografin
Number of subjects: 22
Study: 31924516

Group type: EXPERIMENTAL
Intervention: Surgical repair
Number of subjects: 58

Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 58
Study: 30907929

Group type: EXPERIMENTAL
Intervention: Superpower Glass intervention plus standard of care applied behavioral analysis therapy
Number of subjects: 71

Group type: COMPARATOR
Intervention: Applied behavioral analysis therapy (control)
Number of subjects: 71
Study: 27836505

Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA) injectable
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) implant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progestin contraception
Number of subjects: 0
Study: 26401577

Group type: EXPERIMENTAL
Intervention: Potassium citrate (K-citrate), 40 mEq daily for 1 year
Number of subjects: 83
Study: 21890295

Group type: EXPERIMENTAL
Intervention: Gadobutrol (1.0M)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Gadoterate meglumine (0.5M)
Number of subjects: 136
Study: 21410944

Group type: EXPERIMENTAL
Intervention: 5 mg dose of methotrexate/day for 5 days
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 5 mg dose of methotrexate
Number of subjects: 25
Study: 19710291

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 2925

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2925
Study: 17347500

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg orally) along with conventional opioid treatment
Number of subjects: 76

Group type: COMPARATOR
Intervention: Conventional opioid treatment
Number of subjects: 76
Study: 16356697

Group type: EXPERIMENTAL
Intervention: Active rTMS (20‐Hz rTMS to the LPF and 1‐Hz rTMS to the RPF)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Active rTMS focused on different regions of the brain (20‐Hz rTMS to an area of relatively low activity and 1‐Hz rTMS to an area showing relatively high activation)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 30
Study: 14687524

Group type: EXPERIMENTAL
Intervention: NO inhalation of 10 ppm
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 12
Study: 10516936

Group type: EXPERIMENTAL
Intervention: Controlled-delivery formulation of 240 mg diltiazem (DIL)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Extended-release formulation of 10 mg felodipine (FEL)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 5 mg amlodipine (AML)
Number of subjects: 2
Study: 7706344

Group type: EXPERIMENTAL
Intervention: External fixation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Closed medullary pinning
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: External fixation and Closed medullary pinning
Number of subjects: 50
Study: 1968329

Group type: EXPERIMENTAL
Intervention: Good therapeutic alliance with therapists within the first 6 months of treatment
Number of subjects: 143

Group type: COMPARATOR
Intervention: Poor therapeutic alliance with therapists
Number of subjects: 143
Study: 7423602

Group type: EXPERIMENTAL
Intervention: 1 g of ascorbic acid as one effervescent tablet once daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 1 g of ascorbic acid
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Cessation of ascorbic acid
Number of subjects: 41
Study: 31949012

Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 303

Group type: COMPARATOR
Intervention: Eculizumab
Number of subjects: 303
Study: 31380690

Group type: EXPERIMENTAL
Intervention: OurRelationship program
Number of subjects: 600

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 600
Study: 29301922

Group type: EXPERIMENTAL
Intervention: BUD/FORM MART
Number of subjects: 1847

Group type: COMPARATOR
Intervention: Comparators
Number of subjects: 1847
Study: 27402549

Group type: EXPERIMENTAL
Intervention: Housing First (HF)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Housing stability
Number of subjects: 432
Study: 24443174

Group type: EXPERIMENTAL
Intervention: Annual low-dose CT screening (CT group)
Number of subjects: 4104

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 4104

Group type: EXPERIMENTAL
Intervention: Both groups (CT + control)
Number of subjects: 4104
Study: 22534465

Group type: EXPERIMENTAL
Intervention: PET/ceCT
Number of subjects: 120

Group type: COMPARATOR
Intervention: PET/ldCT
Number of subjects: 120
Study: 20692602

Group type: EXPERIMENTAL
Intervention: Lactoferrin-enriched fermented milk (200 mg of lactoferrin daily)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (fermented milk only)
Number of subjects: 36
Study: 17985199

Group type: EXPERIMENTAL
Intervention: Economical stress
Number of subjects: 213
Study: 16003295

Group type: EXPERIMENTAL
Intervention: SOM230 (100 microg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: SOM230 (250 microg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Octreotide (100 microg)
Number of subjects: 12
Study: 12421057

Group type: EXPERIMENTAL
Intervention: Auditory sequences (unimodal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Visual sequences (unimodal)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bimodal conditions (auditory and visual sequences)
Number of subjects: 0
Study: 10353670

Group type: COMPARATOR
Intervention: Bolus infusion of 50 mg/kg tranexamic acid at the end of cardiopulmonary bypass (control group)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Bolus infusion of 50 mg/kg tranexamic acid at the beginning of cardiopulmonary bypass (group A)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Bolus infusion of 50 mg/kg tranexamic acid at the beginning of cardiopulmonary bypass and continuous infusion of 10 mg/kg per h for 6 h after cardiopulmonary bypass (group B)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 46
Study: 8745671

Group type: EXPERIMENTAL
Intervention: Concomitant radiotherapy with cisplatin (CDDP) 20 mg/m2, 5-fluorouracil (5-FU) 400 mg/m2 (day 1 to day 4), and mitomycin C (MMC) 10 mg/m2 (day 1) for three cycles at days 1, 21, and 42.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Concomitant radiotherapy with cisplatin (CDDP), 5-fluorouracil (5-FU), and mitomycin C (MMC).
Number of subjects: 27
Study: 2330934

Group type: EXPERIMENTAL
Intervention: Pro drinking driving condition
Number of subjects: 36

Group type: COMPARATOR
Intervention: Against drinking driving condition
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Male subjects
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Female subjects
Number of subjects: 36
Study: 7028084

Group type: EXPERIMENTAL
Intervention: 1% chlortetracycline eye ointment
Number of subjects: 85

Group type: COMPARATOR
Intervention: 1% rifampicin eye ointment
Number of subjects: 85
Study: 31834125

Group type: EXPERIMENTAL
Intervention: Visit-to-visit variability (VVV) in blood pressure (BP)
Number of subjects: 3091

Group type: EXPERIMENTAL
Intervention: Coefficient of variation SBP
Number of subjects: 3091

Group type: EXPERIMENTAL
Intervention: Standard deviation (SD) or coefficient of variation DBP
Number of subjects: 3091

Group type: EXPERIMENTAL
Intervention: Visit-to-visit variability in BP
Number of subjects: 3091
Study: 31179916

Group type: EXPERIMENTAL
Intervention: Combined center- and home-based intervention
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Center-based intervention only
Number of subjects: 444

Group type: COMPARATOR
Intervention: Comparison (control group)
Number of subjects: 444
Study: 28826645

Group type: EXPERIMENTAL
Intervention: Oral ketorolac 20 mg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 24867904

Group type: EXPERIMENTAL
Intervention: Interferential current (IFC)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Both IFC and TENS
Number of subjects: 64
Study: 23998970

Group type: EXPERIMENTAL
Intervention: Morning-dose group (20 mg controlled-release simvastatin in the morning, placebo in the evening)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Evening-dose group (placebo in the morning, 20 mg controlled-release simvastatin in the evening)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 132
Study: 21832863

Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray 0.1% (ANS)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Levocabastine nasal spray 0.05% (LNS)
Number of subjects: 244
Study: 19286422

Group type: EXPERIMENTAL
Intervention: Endocrine treatment plus radiotherapy
Number of subjects: 875

Group type: COMPARATOR
Intervention: Endocrine treatment alone
Number of subjects: 875
Study: 17403840

Group type: EXPERIMENTAL
Intervention: Community-wide educational intervention (mailed newsletters and educational materials)
Number of subjects: 1106

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1106

Group type: EXPERIMENTAL
Intervention: Subanalysis for Medicaid-insured children
Number of subjects: 1106
Study: 14651948

Group type: EXPERIMENTAL
Intervention: Immunization during an important viva voce examination (n=22)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Immunization during examination-free term time (n=23)
Number of subjects: 45
Study: 10993641

Group type: EXPERIMENTAL
Intervention: Radiologically detectable bone lesions
Number of subjects: 51

Group type: COMPARATOR
Intervention: No bone lesions
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: MYCN amplification
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Urinary vanillylmandelic/homovanillic acid ratio
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Serum ferritin levels
Number of subjects: 51
Study: 9063764

Group type: EXPERIMENTAL
Intervention: 1,500 mg L-arginine and 1,500 mg L-lysine ingestion followed by resistance exercise (Trial B)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo ingestion followed by resistance exercise (Trial A)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 1,500 mg L-arginine and 1,500 mg L-lysine ingestion without exercise (Trial C)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo ingestion without exercise (Trial D)
Number of subjects: 16
Study: 8366413

Group type: EXPERIMENTAL
Intervention: Sonic scaler plastic insert
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sonic metal insert
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Sonic plastic insert
Number of subjects: 23
Study: 3101535

Group type: EXPERIMENTAL
Intervention: Ro 15-1788 (0.5 to 2.0 mg)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Ro 15-1788 (0.3 to 0.8 mg)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Ro 15-1788
Number of subjects: 38
Study: 30455091

Group type: COMPARATOR
Intervention: Standard physical therapy interventions (manual therapy and exercise)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Standard physical therapy and trigger point dry needling
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Standard physical therapy and sham trigger point dry needling
Number of subjects: 130
Study: 29274471

Group type: EXPERIMENTAL
Intervention: Paired associative stimulation (PAS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 24
Study: 26995298

Group type: EXPERIMENTAL
Intervention: Escitalopram, Sertraline, or Venlafaxine extended-release (8 weeks treatment)
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Matched healthy participants (no medication or intervention)
Number of subjects: 1008
Study: 25498992

Group type: EXPERIMENTAL
Intervention: Home telemonitoring (n=47); patients measured body weight, blood pressure, pulse, and answered symptom-related questions weekly, reporting to a heart failure nurse via a mobile app.
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Home telemonitoring (n=47); patients had increased health care resource use.
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Home telemonitoring (n=47); adherence rate was close to 90%.
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Home telemonitoring (n=47); technology feedback was collected.
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (n=47); received multidisciplinary treatment according to standard practices.
Number of subjects: 94
Study: 22749594

Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine and/or 7-valent pneumococcal conjugate vaccine (PCV7)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Non-splenectomized non-vaccinated control group
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Splenectomized patients vaccinated
Number of subjects: 147
Study: 20031392

Group type: EXPERIMENTAL
Intervention: Oral clodronate 1600 mg/d
Number of subjects: 851

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 851
Study: 18765480

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 15886667

Group type: EXPERIMENTAL
Intervention: Primary amputation (African American patients)
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Repeat amputation (African American patients)
Number of subjects: 513
Study: 12679835

Group type: EXPERIMENTAL
Intervention: Mini Nutritional Assessment (MNA)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Subjective Global Assessment (SGA)
Number of subjects: 43
Study: 10864113

Group type: EXPERIMENTAL
Intervention: Hot, humid air delivered by mask
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Hot, humid air inhaled in a chamber
Number of subjects: 18
Study: 8818092

Group type: EXPERIMENTAL
Intervention: PGE1 (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Epidural anesthesia (n = 10)
Number of subjects: 20
Study: 1424324

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 3878719

Group type: EXPERIMENTAL
Intervention: Propofol with lorazepam premedication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol with papaveretum and hyoscine premedication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unpremedicated patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol (with lignocaine 0.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0
Study: 31026742

Group type: EXPERIMENTAL
Intervention: COP-1 (copulations within the first 4 h after estrus)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: COP-2 (copulations around 16 h after estrus)
Number of subjects: 48

Group type: COMPARATOR
Intervention: CON (noncopulations, only mounts)
Number of subjects: 48
Study: 28704328

Group type: COMPARATOR
Intervention: Dexamethasone (DXM) alone (20 mg IV)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) plus Hydrocortisone (HCT) (100 mg IV)
Number of subjects: 86
Study: 25341431

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment, 30-min weekly for 3 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 15
Study: 23346948

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 660

Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 660
Study: 21255760

Group type: EXPERIMENTAL
Intervention: XIENCE V
Number of subjects: 1002

Group type: COMPARATOR
Intervention: TAXUS
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: XIENCE V and TAXUS
Number of subjects: 1002
Study: 19908310

Group type: COMPARATOR
Intervention: Placebo (DATATOP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PRECEPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (DATATOP) vs Placebo (PRECEPT)
Number of subjects: 0
Study: 16391584

Group type: EXPERIMENTAL
Intervention: 15 microg (600 IU) vitamin D(3) and 1,500 mg calcium/day for 8 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1,500 mg calcium/day for 8 weeks (control group)
Number of subjects: 30
Study: 15292721

Group type: EXPERIMENTAL
Intervention: Acupressure on P6 point (Nei-Guan) for 5 minutes at least 3 times a day before chemotherapy and mealtimes
Number of subjects: 40

Group type: COMPARATOR
Intervention: Regular antiemesis medication (Control group)
Number of subjects: 40
Study: 11441413

Group type: EXPERIMENTAL
Intervention: 100 mg/m2 docetaxel for three cycles before definitive surgery or radiotherapy
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Induction docetaxel followed by curative radiotherapy
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Neoadjuvant docetaxel in combination with cisplatin or carboplatin
Number of subjects: 274
Study: 9158047

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (20 mg/kg/day intravenously in 150 ml of saline for five days)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (150 ml of saline without POF)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 51
Study: 8198036

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg plus hydrochlorothiazide 12.5 mg (group 2)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Enalapril 20 mg (group 1)
Number of subjects: 38
Study: 3681565

Group type: EXPERIMENTAL
Intervention: Health care professional judgements of substance use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adolescent self-reports of substance use
Number of subjects: 0